

12. Eur J Pharmacol. 2020 Apr 15;873:172957. doi: 10.1016/j.ejphar.2020.172957. Epub 
2020 Jan 28.

Selective metabotropic glutamate receptor 2 positive allosteric modulation
alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the
MPTP-lesioned marmoset.

Sid-Otmane L(1), Hamadjida A(2), Nuara SG(3), Bédard D(2), Gaudette F(4), Gourdon
JC(3), Michaud V(5), Beaudry F(6), Panisset M(7), Huot P(8).

Author information: 
(1)Département de Pharmacologie et Physiologie, Université de Montréal, Montreal,
QC, Canada.
(2)Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal,
QC, Canada.
(3)Comparative Medicine & Animal Resource Centre, McGill University, Montreal,
QC, Canada.
(4)Plateforme de Pharmacocinétique, Centre de Recherche du Centre Hospitalier de 
l'Université de Montréal, Montreal, QC, Canada.
(5)Pharmacotherapy and Translational Research, College of Pharmacy, University of
Florida, Lake Nona Campus, Orlando, FL, USA.
(6)Groupe de Recherche en Pharmacologie Animale du Québec, Département de
Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal,
Saint-Hyacinthe, QC, Canada.
(7)Unité des troubles du mouvement André-Barbeau, Service de Neurologie,
Département de Médecine, Centre Hospitalier de l'Université de Montréal,
Montreal, QC, Canada; Département de Neurosciences, Université de Montréal,
Montreal, QC, Canada.
(8)Département de Pharmacologie et Physiologie, Université de Montréal, Montreal,
QC, Canada; Neurodegenerative Disease Group, Montreal Neurological Institute,
Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill
University, Montreal, QC, Canada; Movement Disorder Clinic, Division of
Neurology, Department of Neurosciences, McGill University Health Centre,
Montreal, QC, Canada. Electronic address: philippe.huot@mcgill.ca.

Psychosis and dyskinesia significantly diminish the quality of life of patients
with advanced Parkinson's disease (PD). Available treatment options are
unfortunately few and their use is limited by adverse effects. We have recently
shown that activation of metabotropic glutamate 2 and 3 (mGlu2/3) receptors
produced significant relief of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced
psychosis-like behaviours (PLBs) and dyskinesia in experimental models of PD.
Here, using the highly-selective mGlu2 positive allosteric modulator (PAM)
LY-487,379, we seek to determine the contribution of selective mGlu2 activation
on both L-DOPA-induced PLBs and dyskinesia, in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate. We first
determined the pharmacokinetic (PK) profile of LY-487,379 in the common marmoset,
following which we administered it (0.1, 1 and 10 mg/kg) or its vehicle to 6
MPTP-lesioned marmosets previously exposed to L-DOPA to elicit stable PLBs and
dyskinesia. We found that LY-487,379 provided a ≈45% reduction of the global PLBs
observed and reduced global dyskinesia score by ≈ 55%. Moreover, LY-487,379
enhanced the anti-parkinsonian effect of L-DOPA, by reducing global parkinsonian 
score by ≈ 15%. Our data suggest that selective mGlu2 positive allosteric
modulation with LY-487,379 may represent a potential therapeutic approach to
alleviate both L-DOPA-induced PLBs and dyskinesia in PD.

Copyright © 2020 Elsevier B.V. All rights reserved.

DOI: 10.1016/j.ejphar.2020.172957 
PMID: 32004527  [Indexed for MEDLINE]

